ICU Medical, Inc. (ICUI)
NEUTRALFundamental
49
Precio
$183.10
Capitalización Bursátil
$4.55B
Parte 1 · Cuánto vale la empresa
Resumen
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$2.16B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$30M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$92M
Patrimonio Neto Total
$2.12B
Pasivo Total
$1.93B
Ratio de Liquidez
2.43
Cobertura de Intereses
0.87
Deuda/EBITDA
5.28
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$102.68
Precio Actual
$183.10
Margen de Seguridad
-78.3%
Rango de Valor Justo
$66.74 - $138.62
Métodos de Estimación
Métricas de Valoración
Ratio P/E
153.40
ROE
0.0%
Ratio P/B
2.12
P/FCF
29.87
Margen Bruto
39.1%
ROIC
1.6%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
1.6%
WACC
8.5%
ROIC − WACC
-6.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (14)
- Gross Margin 39.1%
- P/FCF 29.87
- P/B Ratio 2.12
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Revenue Growth 5Y 11.9%
- Analyst Consensus 92% Buy
- Earnings Surprise avg 20.3%
- Earnings Quality (OCF/NI) 7.86
- Share Dilution 0.1%
- Net Margin Trend 1.4% vs -1.6%
- Piotroski F-Score 7/9
Fallido (12)
- EPS shows upward trend
- EPS CAGR -19.56%
- Price CAGR 2.18%
- ROIC 1.6%
- Operating Margin 3.3%
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 2.2%
No disponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
El número de acciones es estable
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Vivek Jain | CEO & Chairman of the Board | 53 |
| Mr. Daniel Woolson | President | 48 |
| Mr. Brian Michael Bonnell | CFO & Treasurer | 51 |
| Mr. Christian B. Voigtlander | Chief Operating Officer | 57 |
| Ms. Virginia Ruth Sanzone | Corporate VP, General Counsel, Secretary & Compliance Officer | 50 |
| Ben Sousa | Chief Information Officer | - |
| Olivia Barrall | Vice President of Human Resources | - |
Riesgo de Auditoría
5
Riesgo del Consejo
4
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
5
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for ICUI, sourced from Markets Gazette.